Novo Nordisk’s market value dropped by $70 billion after issuing a profit warning and appointing Maziar Mike Doustdar as new CEO to combat competition in the obesity drug market. Sales growth outlook for 2025 was reduced, leading to a nearly 30% stock plunge. Novo faces challenges from copycats of its drugs.

Doustdar, an insider at Novo since 1992, is tasked with increasing urgency and executing differently to address the company’s issues. Investors and analysts had suggested an American CEO. Novo must revive its performance in the U.S., where Zepbound prescriptions surpassed Wegovy’s this year. One million U.S. patients still use compounded GLP-1s despite FDA ban.

Novo’s market value has declined significantly this year, losing ground to rivals like Eli Lilly in the U.S. The company faces challenges in rebuilding trust and addressing the issue of unlawful compounding of its drugs. The new CEO’s priority is to enhance Novo’s performance in the U.S. market, where it faces stiff competition.

Read more at Yahoo Finance: Wegovy maker Novo’s profit warning triggers $70 billion share rout